Stock Events

Stock Events

Exelixis 

$44.42
211
+$0.25+0.57% Tuesday 20:00

Statistics

Day High
45.2
Day Low
44.13
52W High
46.85
52W Low
34.54
Volume
2,837,640
Avg. Volume
-
Mkt Cap
11.54B
P/E Ratio
15.71
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
0.36
0.55
0.75
0.94
Expected EPS
0.806522
Actual EPS
N/A

Financials

33.73%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
4.64BRevenue
1.57BNet Income

Analyst Ratings

45Average Price Target
The highest estimate is 54.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
17%
Hold
83%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EXEL. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb competes in the oncology space with a broad portfolio of cancer treatments, overlapping with Exelixis's focus on cancer therapeutics.
Merck
MRK
Mkt Cap277.02B
Merck is a leading competitor in the oncology market, particularly with its blockbuster cancer drug Keytruda, which competes in indications similar to those of Exelixis's products.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a diverse oncology portfolio that includes treatments for various types of cancer, directly competing with Exelixis's cancer therapies.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca operates in the same therapeutic areas as Exelixis, with a strong focus on oncology and a pipeline of cancer drugs that compete with Exelixis's offerings.
Roche
RHHBY
Mkt Cap328.49B
Roche, through its Genentech division, develops and markets oncology drugs that compete with Exelixis's cancer treatments, particularly in the areas of targeted therapy and immunotherapy.
Novartis
NVS
Mkt Cap279.67B
Novartis competes with Exelixis in the oncology sector, offering a range of cancer treatments that overlap with Exelixis's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences, with its acquisition of Kite Pharma, has expanded its oncology portfolio, competing with Exelixis in the cancer treatment market.
AMGEN
AMGN
Mkt Cap178B
Amgen has a presence in the oncology market with treatments that compete against Exelixis's cancer therapies, including targeted therapies and biologics.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals competes in the oncology space with a focus on innovative cancer treatments, including immunotherapies that rival Exelixis's products.
Incyte
INCY
Mkt Cap19.36B
Incyte Corporation has a portfolio of oncology products that directly compete with Exelixis's cancer therapies, particularly in the areas of targeted therapy and immunotherapy.

About

There is no Profile data available for EX9.SG.
Show more...
CEO
Dr. Stelios Papadopoulos Ph.D.
Employees
1147
Country
United States
ISIN
US30161Q1040

Listings

MI
IT
1EXEL.MI
STU
DE
EX9.STU
MU
DE
EX9.MU
BOATS
BOATS
EXEL.BOATS

0 Comments

Share your thoughts

FAQ

What is Exelixis stock price today?▼
The current price of EXEL is $44.42 USD — it has increased by +0.57% in the past 24 hours. Watch Exelixis stock price performance more closely on the chart.
What is Exelixis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Exelixis stocks are traded under the ticker EXEL.
Is Exelixis stock price growing?▼
EXEL stock has fallen by -0.6% compared to the previous week, the month change is a +1% rise, over the last year Exelixis has showed a +20.51% increase.
What is Exelixis market cap?▼
Today Exelixis has the market capitalization of 11.54B
When is the next Exelixis earnings date?▼
Exelixis is going to release the next earnings report on August 05, 2026.
What were Exelixis earnings last quarter?▼
EXEL earnings for the last quarter are 0.87 USD per share, whereas the estimation was 0.76 USD resulting in a +13.76% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Exelixis revenue for the last year?▼
Exelixis revenue for the last year amounts to 4.64B USD.
What is Exelixis net income for the last year?▼
EXEL net income for the last year is 1.57B USD.
How many employees does Exelixis have?▼
As of May 06, 2026, the company has 1,147 employees.
In which sector is Exelixis located?▼
Exelixis operates in the Health & Wellness sector.
When did Exelixis complete a stock split?▼
Exelixis has not had any recent stock splits.
Where is Exelixis headquartered?▼
Exelixis is headquartered in Alameda, United States.